hrs-1167
Small moleculeexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 23, 2022 (NCT05473624)
Timeline
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 10INHIBITOR
PARP10 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06719973 | Phase 1 | Jan 6, 2025 | Merck KGaA, Merck Serono |
| NCT06689163 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06509906 | Phase 1 | Oct 8, 2024 | Merck KGaA, Merck Serono |
| NCT06568094 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2024 | Hengrui Therapeutics, Inc. |
| NCT06421935 | Phase 1 | Aug 7, 2024 | Merck KGaA, Merck Serono |
| NCT06516289 | Phase 2 | Jul 31, 2024 | Fudan University |
| NCT06308406 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2024 | Hengrui Therapeutics, Inc. |
| NCT06198556 | Phase 1 | Jan 14, 2024 | Hengrui Therapeutics, Inc. |
| NCT05473624 | Phase 1 | Aug 23, 2022 | Hengrui Therapeutics, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2022 |
| Merck KGaA | For profit | 3 | 0 | 1 | 2024 |
| Merck Serono | For profit | 3 | 3 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1